Immunological Study on neuroleptic response in schizophrenia

精神分裂症抗精神病药反应的免疫学研究

• 批准号: 07671069
• 负责人: AKIYAMA Kazufumi
• 金额: $ 1.47万
• 依托单位: Okayama University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671069/
• 关键词: Schizophrenia; Cytokine; Interleukin-6; Interleukin-1; Interleukin-2; Interleukin-2 Soluble receptor alpha; 抗精神病薬; 免疫; 可溶性インターロイキン2受容体; インターロイキン; ホモバニリン酸

The present study measured serum levels of interleukin soluble receptor alpha (IL-2sRalpha), interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1ra) both before and during the neuroleptic administration of 8-week protocol in schizophrenia subjects in comparison with normal controls. Serum levels of IL-2sRalpha, IL-6 and IL-1ra at week 0,1,4 and 8 of the schizophrenia patients were significantly higher than those for the controls. Serum levels of IL-2sRalpha and IL-6 were significantly higher in neuroleptic-naive schizophrenia patients at week 0 than in the controls. In the schizophrenia patients, there were significant negative correlations between serum levels IL-2sRalpha or IL-1ra at week 1 and age of onset, and a significant positive correlation between IL-6 levels at week 4 and duration of illness. There were significant positive correlations between IL-2sRalpha levels at week 0 and 1 and psychopathology evaluated by means of PANSS at week 1 and 4. IL-1ra levels at week 1 were significantly (positively) correlated with positive symptoms at week 1 and negative symptoms at week 8. The present study supports a suggestion that alterations of immune system are involved in pathophysiolog of schizophrenia.

本研究测量了白介素可溶性受体α（IL-2Sralpha），白介素6（IL-6）和白介素-1受体拮抗剂（IL-1RA）的血清水平，均与正常对照组相比。第0,1,4周的IL-2骨，IL-6和IL-1RA的血清水平明显高于对照组的血清水平。在第0周，神经肌饮质精神分裂症患者的血清-2Sralpha和IL-6水平明显高于对照组。在精神分裂症患者中，在第1周和发病年龄的血清水平IL-2Sralpha或IL-1RA之间存在显着的负相关，并且在第4周第4周的IL-6水平与疾病持续时间之间存在显着的正相关。 There were significant positive correlations between IL-2sRalpha levels at week 0 and 1 and psychopathology evaluated by means of PANSS at week 1 and 4. IL-1ra levels at week 1 were significantly (positively) correlated with positive symptoms at week 1 and negative symptoms at week 8. The present study supports a suggestion that alterations of immune system are involved in pathophysiolog of schizophrenia.

项目成果

秋山一文、児玉匡史、田中有史、柳井広之、柏原健一、清水義雄他: "メタンフェタミン慢性投与後に発現する遺伝子検索に関する研究精神分裂病患者血清中のインターロイキン-2可溶性受容体に関する研究" 厚生省「精神神経疾患研究委託費」精神分裂病の本態に関する生化学的、生理学的、遺伝医学的研究、平成8年度研究報告書. (印刷中). (1997)

Kazufumi Akiyama、Tadashi Kodama、Yuji Tanaka、Hiroyuki Yanai、Kenichi Kashihara、Yoshio Shimizu 等：“寻找长期服用甲基苯丙胺后表达的基因的研究精神分裂症患者血清中白细胞介素 2 可溶性受体的研究”部健康与福利部《精神科“关于精神分裂症本质的生化、生理和遗传医学研究，神经系统疾病研究报告》（正在出版）。（1997）

Kazufumi AKIYAMA: "Plasma homovanillic acid levels and the rapeutic outcome in schizophrenics : companson of neuroleptic-naive first episode patients and patients with disease exacerbation" Biological Psychiatry. 38. 639-648 (1995)

Kazufumi AKIYAMA：“精神分裂症患者的血浆高香草酸水平和治疗结果：首次服用抗精神病药物的患者和疾病恶化患者的同伴”生物精神病学。

Masafumi Kodama, Kazufumi Akiyama et al: "A robust in crease in expression of arc gene an effector immediate eary gene,in the rat brain after acute and chronic methamphetamine administration" Brain Research. (in press). (1998)

Masafumi Kodama、Kazufumi Akiyama 等人：“在急性和慢性服用甲基苯丙胺后，大鼠大脑中 arc 基因（效应器立即早期基因）的表达显着增加”《大脑研究》。

秋山 一文: "精神疾患の仮説α.生物モデル4)脆弱性仮説(2)自己免疫仮説" こころの臨床. 17(印刷中). (1998)

Kazufumi Akiyama：“精神疾病的假设α。生物模型4）脆弱性假设（2）自身免疫假设”《临床心理学》17（出版中）。